Effect of the glycoprotein IIb/IIIa inhibitor tirofiban on concentrations of whole blood choline in acute coronary syndromes

Laboratory Medicine

Volumn 39, Issue 6, 2008, Pages 349-355

  Storm, Christian ^a   Danne, Oliver ^a   Lueders, Christian ^a   Frei, Ulrich ^a   Möckel, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; FIBRINOGEN RECEPTOR ANTAGONIST; PHOSPHOLIPASE D; TIROFIBAN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; RETROSPECTIVE STUDY; THROMBOCYTE ACTIVATION;

EID: 59949103916     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/0TQB1HAUX9JFU1B0     Document Type: Article

References (45)

1. Danne O, Möckel M, Lueders C, et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol. 2003; 91:1060-1067.
2. Danne O, Lueders C, Storm C, et al. Whole blood choline and plasma choline concentration for early risk-stratification of troponin I-negative acute coronary syndromes [abstract]. Circulation. 2003;108:S468.
3. Spector AA. Plaque rupture, lysophosphatidic acid, and thrombosis. Circulation. 2003;108:641-643.
4. Siess W, Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. J Cell Biochem. 2004;92:1086-1094.
5. Haseruck N, Erl W, Pandey D, et al. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: Involvement of P2Y1 and P2Y12 receptors. Blood. 2004; 103:2585-2592.
6. Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 1999;96(12):6931-6936.
7. Chiang TM. Activation of phospholipase D in human platelets by collagen and thrombin and its relationship to platelet aggregation. Biochim Biophys Acta. 1994;1224:147-155.
8. Gomez-Munoz A, Martens JS, Steinbrecher UP. Stimulation of phospholipase D activity by oxidized LDL in mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol. 2000;20:135-143.
9. Williger BT, Ho WT, Exton JH. Phospholipase D mediates matrix metalloproteinase-9 secretion in phorbol ester-stimulated human fibrosarcoma cells. J Biol Chem. 1999;274:735-738.
10. Cox DA, Cohen ML. Relationship between phospholipase D activation and endothelial vasomotor dysfunction in rabbit aorta. J Pharmacol Exp Ther. 1997;283:305-311.
11. Smyth SS, Hillery CA, Parise LV. Fibrinogen binding to purified platelet glycoprotein IIb-IIIa (integrin alpha IIb beta 3) is modulated by lipids. J Biol Chem. 1992;267:15568-15577.
12. Brass LF, Manning DR, Cichowski K, et al. Signaling through G proteins in platelets: To the integrins and beyond. Thromb Haemost. 1997;78:581-589.
13. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998; 338:1498-1505.
14. Cannon CP, Weintraub WS, Demopoulos LA, et al. TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy) - Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
15. Danne O, Lueders C, Storm C, et al. Whole-blood hypercholinemia and coronary instability and thrombosis. Clin Chem. 2005;51:1315-1317.
16. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
17. Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol. 2004;43:958-965.
18. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148-e304.
19. Bertrand ME, Simoons ML, Fox KA, et al. Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809-1840.
20. Danne O, Lueders C, Storm C, et al. Whole blood choline and plasma choline in acute coronary syndromes: Prognostic and pathophysiological implications. Clin Chim Acta. 2007;383:103-109.
21. Sabatine MS, Morrow DA, Giugliano RP, et al. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: A comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004;109:874-880.
22. Ottervanger JP, Armstrong P, Barnathan ES, et al. GUSTO IV-ACS Investigators. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: One-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV - Acute Coronary Syndrome) Trial. Circulation. 2003;107:437-442.
23. Morrow DA, Sabatine MS, Antman EM, et al. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). Am J Cardiol. 2004;94:774-776.
24. Bolognese L. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes. Curr Med Res Opin. 2007;154:39-45.
25. Glaser R, Glick HA, Herrmann HC, et al. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/ IIIa inhibitors for acute coronary syndromes: A cost-effectiveness analysis. J Am Coll Cardiol. 2006;47:538-540.
26. Martinson EA, Scheible S, Greinacher A, et al. Platelet phospholipase D is activated by protein kinase C via an integrin alpha IIb beta 3-independent mechanism. Biochem J. 1995;310:623-628.
27. Exton JH. Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta. 1994;1212:26-42.
28. Nonne C, Lenain N, Hechler B, et al. Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity. Arterioscler Thromb Vasc Biol. 2005;25:1293-1298.
29. Ercan E, Bozdemir H, Tengiz I, et al. Decreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectoris. Thromb J. 2004;2:4.
30. Brühl A, Hafner G, Loffelholz K. Release of choline in the isolated heart, an indicator of ischemic phospholipid degradation and its protection by ischemic preconditioning: No evidence for a role of phospholipase D. Life Sci. 2004;75:1609-1620.
31. Moraru II, Popescu LM, Maulik N, et al. Phospholipase D signaling in ischemic heart. Biochim Biophys Acta. 1992;1139:148-154.
32. Sarri E, Garcia-Dorado D, Abellan A, et al. Effects of hypoxia, glucose deprivation and acidosis on phosphatidylcholine synthesis in HL-1 cardiomyocytes. CTP:phosphocholine cytidylyltransferase activity correlates with sarcolemmal disruption. Biochem J. 2006;394:325-334.
33. Lochner A, de Villiers, M. Phosphatidylcholine biosynthesis in myocardial ischemia. J Mol Cell Cardiol. 1989;21:151-163.
34. Hatch GM, Choy PC. Effect of hypoxia on phosphatidylcholine biosynthesis in the isolated hamster heart. Biochem J. 1990;268:47-54.
35. Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/ IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol. 2004;43:276-283.
36. Januzzi JL, Hahn SS, Chae CU, et al. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. Am J Cardiol. 2000;86:713-717.
37. Leoncini M, Toso A, Maioli M, et al. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. Am Heart J. 2005;150:401.
38. Stewart JT, French JK, Theroux P, et al. Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol. 1998;31:1499-1505.
39. Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol. 2006;47:522-528.
40. de Winter RJ, Windhausen F, Cornel JH, et al. Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353:1095-1104.
41. Adamczyk M, Brashear RJ, Mattingly PG, et al. Homogeneous chemiluminescent assays for free choline in human plasma and whole blood. Anal Chim Acta. 2006;579:61-67.
42. Adamczyk M, Brashear RJ, Mattingly PG. Rapid high-throughput detection of peroxide with an acridinium-9-carboxamide: A homogeneous chemiluminescent assay for plasma choline. Bioorg Med Chem Lett. 2006;16:2407-2410.
43. Adamczyk M, Brashear RJ, Mattingly PG. Choline concentration in normal blood donor and cardiac troponin-positive plasma samples. Clin Chem. 2006;52:2123-2124.
44. Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810-824.
45. Wu AH. Markers for early detection of cardiac diseases. Scand J Clin Lab Invest Suppl. 2005;240:112-121.